Thomas Saylor is retiring as CEO of Arecor, the position in which he has effectively served for the past eight years.
Although Tom has decided to retire from full time responsibility as CEO he has been asked by the Board to remain as a non-Executive Director of Arecor where he can continue to contribute his network, skills and experience to the ongoing success of the business.
Tom will be succeeded by Dr Sarah Howell who has served as Chief Operating Officer and Vice President for Corporate Development. Sarah brings very considerable experience from executive roles in the pharmaceutical industry including, most recently, as Vice President for CMC and Technical Development of BTG plc.
Arecor is a leader in delivery of superior biopharmaceutical formulations via the stabilisation of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Many proteins, peptides or vaccines are too unstable in liquid form to develop ready-to-use drugs, or are unstable at high concentrations. Arecor has developed an innovative and proprietary formulation technology platform to enable superior biopharmaceutical with the potential to significantly enhance the delivery of therapeutic medicines to patients. It has partnered with the world’s leading pharmaceutical and biotech companies to enhance the commercial value and practical utility of many different types of therapeutic proteins, peptides and vaccines. Arecor is based at the Cambridge Science Park in the UK and has a highly talented scientific team.